Cytokinetics (NASDAQ:CYTK) Price Target Raised to $96.00

Cytokinetics (NASDAQ:CYTK) had its price objective upped by equities research analysts at Citizens Jmp from $88.00 to $96.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s price target indicates a potential upside of 36.95% from the stock’s current price.

Several other equities research analysts have also weighed in on the company. Royal Bank Of Canada lifted their price objective on Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Truist Financial boosted their target price on shares of Cytokinetics from $84.00 to $92.00 and gave the company a “buy” rating in a report on Tuesday, February 3rd. B. Riley Financial increased their target price on Cytokinetics from $90.00 to $108.00 and gave the stock a “buy” rating in a research report on Wednesday, January 21st. Needham & Company LLC lifted their price target on Cytokinetics from $72.00 to $84.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Finally, The Goldman Sachs Group set a $95.00 price objective on Cytokinetics and gave the company a “buy” rating in a research note on Thursday, December 18th. Sixteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Cytokinetics currently has an average rating of “Moderate Buy” and a consensus price target of $88.78.

Cytokinetics Stock Up 2.7%

CYTK opened at $70.10 on Wednesday. Cytokinetics has a twelve month low of $29.31 and a twelve month high of $70.98. The company’s 50-day moving average price is $64.14 and its two-hundred day moving average price is $58.32. The stock has a market cap of $8.57 billion, a price-to-earnings ratio of -11.14 and a beta of 0.54.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The company had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same quarter last year, the firm posted ($1.26) EPS. The company’s revenue was up 4.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Cytokinetics will post -5.24 earnings per share for the current year.

Insider Activity at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 2,200 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $61.24, for a total value of $134,728.00. Following the transaction, the executive vice president directly owned 138,552 shares in the company, valued at approximately $8,484,924.48. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrew Callos sold 52,486 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $65.95, for a total transaction of $3,461,451.70. Following the completion of the transaction, the executive vice president owned 50,660 shares of the company’s stock, valued at $3,341,027. This trade represents a 50.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 151,385 shares of company stock valued at $9,817,158 in the last ninety days. Insiders own 3.40% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

A number of hedge funds have recently made changes to their positions in the business. Woodline Partners LP boosted its stake in shares of Cytokinetics by 676.1% in the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock valued at $90,559,000 after purchasing an additional 1,435,422 shares in the last quarter. Norges Bank bought a new stake in Cytokinetics in the second quarter worth $39,122,000. Deep Track Capital LP boosted its position in Cytokinetics by 17.8% during the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after buying an additional 650,000 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in shares of Cytokinetics by 151,987.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock valued at $35,949,000 after buying an additional 565,393 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. purchased a new position in shares of Cytokinetics in the second quarter worth about $18,328,000.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in U.S., China and Europe; U.S. launch underway with first prescriptions dispensed within days — this turns near-term revenue into a tangible commercial story and is the biggest immediate catalyst. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue materially exceeded expectations: Q4 revenue ~$17.7M vs. consensus near $8M — suggests early commercial uptake or other revenue sources are ahead of models. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Strong balance sheet: company reported ~ $1.2 billion in cash, cash equivalents and investments as of 12/31/25 and provided 2026 financial guidance — gives runway to support commercialization and ongoing trials. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Near-term clinical catalyst: company expects to share ACACIA‑HCM topline results in Q2 2026 — a positive binary event that could drive further re-rating if favorable. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst views are mixed on CYTK’s near-term outlook — some focus on commercial upside while others remain cautious on uptake and margins. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK) and Tandem Diabetes Care (TNDM)
• Neutral Sentiment: Full earnings and call transcripts are available for details on commercialization plans and cost structure; useful for investors who want management tone and phasing. Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Small EPS miss and widening loss: GAAP EPS was -$1.50 vs. consensus -$1.48, and the loss increased versus prior year (-$1.26) — ongoing operating losses remain a drag until revenue scales. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.